Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | EML4 - ALK ALK V1180L |
Therapy | Ceritinib |
Indication/Tumor Type | lung adenocarcinoma |
Response Type | predicted - sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
EML4 - ALK ALK V1180L | lung adenocarcinoma | predicted - sensitive | Ceritinib | Case Reports/Case Series | Actionable | In a retrospective analysis, Zykadia (ceritinib) treatment resulted in a partial response with a progression-free survival of 7.3 months, overall survival of 26.3 months, and a duration of treatment of 8.2 months in a patient with lung adenocarcinoma harboring EML4-ALK (e6:e20) with ALK V1180L (PMID: 39500140). | 39500140 |
PubMed Id | Reference Title | Details |
---|---|---|
(39500140) | Molecular Tumor Board of the University Medical Center Groningen (UMCG-MTB): outcome of patients with rare or complex mutational profiles receiving MTB-advised targeted therapy. | Full reference... |